ClinicalTrials.gg
CompletedNCT03624010Updated Apr 22, 2026Results posted

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

A Phase 2 interventional study of Levosimendan in Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction and Heart Failure With Normal Ejection Fraction, sponsored by Tenax Therapeutics, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Tenax Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies testing simendan in Heart Failure — 2 open to participants now, 2 under way, 2 of them phase 3. Simendan · Heart Failure.

Enrollment
26th of 32
35 · median 76
Started
2019
with 2 others
Phase 2
6 of 32
none open now
Registered
24th of 32
by date
Lead sponsor
2 of 32
Tenax Therapeutics, Inc.

Among the 32 studies testing simendan in Heart Failure, this one is the 26th largest by enrollment, is one of 3 that started in 2019, is one of 6 in phase 2, and was the 24th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 32 studies testing simendan in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About simendan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing simendan in Heart Failure, or all of them as a file.
02

Study summary

PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.

Read the detailed description

This study will enroll PH-HFpEF patients that have completed a controlled levosimendan study. These patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.

03

Conditions studied

  • Hypertension Pulmonary Secondary Heart Failure
  • Right Sided Heart Failure With Normal Ejection Fraction
  • Heart Failure With Normal Ejection Fraction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide a personally signed and dated document prior to initiation of any study-related procedures that are not considered standard of care.
  2. Completed double-blind therapy in a PH-HFpEF clinical study sponsored by Tenax Therapeutics, Inc.
  3. May, in the opinion of the Investigator, benefit from continued levosimendan treatment.
  4. Female patients of must agree to use a highly effective method of .
  5. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Discontinued treatment in the parent study for any reason other than study completion or Sponsor termination of the study.
  2. Pregnant or breastfeeding women.
  3. Local access to commercially available levosimendan
  4. Inability to comply with planned study procedures
  5. Patients with scheduled lung or heart transplant or cardiac surgery
  6. Dialysis developed since enrollment in parent study (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafiltration)
  7. Estimated (eGFR) \<30 mL/min/1.73m2
  8. Liver dysfunction with Class B or C (see Attachment 2)
  9. Evidence of systemic bacterial, systemic fungal, or viral infection to treatment
  10. Weight >150kg
  11. Systolic blood pressure (SBP) cannot be managed to ensure SBP >100 mmHg at initiation of study drug
  12. Heart rate >100 bpm with study drug, persistent for at least 10 minutes at screening.
  13. \< 80 g/L
  14. Serum potassium \< 3.0 mmol/L or > 5.5 mmol/L at baseline that is unresponsive to management
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Other
    Levosimendan Open-Label

    Initial: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion. Ongoing patients are transitioned to daily oral levosimendan (1mg capsules TID)

    Drug: Levosimendan

Interventions

  • DrugSimendanStudies of SimendanSimendan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Initial: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for a weekly 24 hour infusion. Transioned to: Daily Levosimendan capsules (1 mg TID)

06

What researchers measure

Primary outcomes

  1. Clinical Safety

    Number of Adverse Events per Patient Population

    Time frame: Duration of study (for up to 2 years); Assessed at Weeks 3, 6, 12, 24, and 48 and Follow-Up Visit (termination visit).

07

Results

Posted Apr 22, 2026
Limitations and caveats
This was an uncontrolled observational study of patients transitioning from a controlled study to open-label levosimendan. After an average of 11.5 months on study, ongoing patients were transitioned from a weekly IV infusion regimen to daily oral levosimendan.

Participant flow

Patients completing the Phase 2 HELP Study (TNX-LVO-04) were consented to open-label levosimendan.

Participant flow — Overall Study
MilestoneLevosimendan Open-Label
Started35
Completed16
Not completed19
Withdrew: Withdrawal by subject10
Withdrew: Adverse event5
Withdrew: Physician decision2
Withdrew: Not provided2

Outcome measures

PrimaryClinical Safety

Number of Adverse Events per Patient Population

Time frame:
Duration of study (for up to 2 years); Assessed at Weeks 3, 6, 12, 24, and 48 and Follow-Up Visit (termination visit).
Reported as:
Count of participants · Participants
Clinical Safety
ParticipantsLevosimendan Open-Label
Clinical Safety33

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levosimendan Open-Label2/35 (5.7%)24/35 (68.6%)15/35 (42.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventLevosimendan Open-Label
Cardiac disordersCardiac disorders13/35
Infections and infestationsInfections and infestations11/35
Metabolism and nutrition disordersMetabolism and nutrition disorders6/35
Renal and urinary disordersRenal and urinary disorders4/35
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders4/35
Gastrointestinal disordersGastrointestinal disorders3/35
General disordersGeneral disorders3/35
Vascular disordersVascular disorders3/35
Blood and lymphatic system disordersBlood and lymphatic system disorders2/35
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders2/35
Most frequent other events
Most frequent other events
EventLevosimendan Open-Label
Cardiac disordersCardiac disorders6/35
Nervous system disordersNervous system disorders5/35
Product issuesProduct Issues4/35
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders3/35
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders3/35
General disordersGeneral disorders2/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Levosimendan IV Transitioned to Levosimendan Capsules (1mg)
Mean68.3 ± 9.56
Sex: Female, Male
Sex: Female, Male(Participants)Levosimendan IV Transitioned to Levosimendan Capsules (1mg)
Female21
Male14
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Levosimendan IV Transitioned to Levosimendan Capsules (1mg)
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White31
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Levosimendan IV Transitioned to Levosimendan Capsules (1mg)
United States35
08

Study locations

9 sites
  • Stanford Healthcare
    Stanford, California 94305, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Minnesota Medical Center
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Presbyterian Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • UW Health University Hospital
    Madison, Wisconsin 53792, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2023, 48 months.

Results were first posted in Apr 2026, 2 years 11 months after primary completion.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 48 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2018
First posted
Aug 9, 2018
StartActual
Apr 9, 2019
Primary completionActual
Apr 25, 2023
CompletionActual
Apr 25, 2023
Results first posted
Apr 22, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03624010
Lead sponsor
Tenax Therapeutics, Inc.
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Apr 9, 2019
Primary completion
Apr 25, 2023
Completion
Apr 25, 2023
Results posted
Apr 22, 2026
Last update
Apr 22, 2026

Study contacts

Stuart Rich, MD
principal investigator · Tenax Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion